Interview with Jeffrey Davis, CEO of Access Pharmaceuticals

In August, OneMedPlace reported on MuGard, a preventive treatment for oral mucositis from Access Pharmaceuticals. MuGard is currently being launched in Europe, and is expected to hit the North American market toward the end of 2009. The worldwide market for oral mucositis preventive therapy in patients with head or neck cancer is estimated to be over $5 billion.  

Access Pharmaceuticals is also developing ProLindac and Thiarabine, two therapeutics to treat various cancers. OneMedPlace recently interviewed CEO Jeffrey Davis about the Dallas-based company’s pipeline, including the latest news on MuGard.

The comments are closed.